BR112017008799A2 - composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal - Google Patents

composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal

Info

Publication number
BR112017008799A2
BR112017008799A2 BR112017008799A BR112017008799A BR112017008799A2 BR 112017008799 A2 BR112017008799 A2 BR 112017008799A2 BR 112017008799 A BR112017008799 A BR 112017008799A BR 112017008799 A BR112017008799 A BR 112017008799A BR 112017008799 A2 BR112017008799 A2 BR 112017008799A2
Authority
BR
Brazil
Prior art keywords
methods
kidney cancer
treating kidney
apilimod
compositions
Prior art date
Application number
BR112017008799A
Other languages
English (en)
Portuguese (pt)
Inventor
Conrad Chris
Lichenstein Henri
M Rothberg Jonathan
BEEHARRY Neil
Beckett Paul
LANDRETTE Sean
Gayle Sophia
Xu Tian
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of BR112017008799A2 publication Critical patent/BR112017008799A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017008799A 2014-11-07 2015-11-06 composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal BR112017008799A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
PCT/US2015/059512 WO2016073877A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of renal cancer

Publications (1)

Publication Number Publication Date
BR112017008799A2 true BR112017008799A2 (pt) 2017-12-19

Family

ID=54548302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008799A BR112017008799A2 (pt) 2014-11-07 2015-11-06 composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal

Country Status (16)

Country Link
US (3) US10206910B2 (enExample)
EP (2) EP3581184B1 (enExample)
JP (1) JP6705828B2 (enExample)
KR (1) KR20170098812A (enExample)
CN (1) CN107249638B (enExample)
AU (1) AU2015342869A1 (enExample)
BR (1) BR112017008799A2 (enExample)
CA (1) CA2966359A1 (enExample)
ES (1) ES2741399T3 (enExample)
HU (1) HUE044557T2 (enExample)
IL (1) IL251905B (enExample)
MX (1) MX377593B (enExample)
PL (1) PL3215158T3 (enExample)
PT (1) PT3215158T (enExample)
RU (1) RU2727802C2 (enExample)
WO (1) WO2016073877A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015209133B2 (en) 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
ES2734081T3 (es) * 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
CN107249638B (zh) 2014-11-07 2021-05-14 人工智能治疗公司 阿匹莫德用于治疗肾癌
JP2019502707A (ja) * 2016-01-21 2019-01-31 ラム・セラピューティクス，インコーポレーテッド 癌をアピリモドで処置するためのバイオマーカー
MX2019002185A (es) * 2016-08-25 2019-09-19 Ai Therapeutics Inc Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.
US20190365771A1 (en) * 2016-10-12 2019-12-05 AI Therapeutics, Inc. Apilimod compositions and methods for using same in the treatment of alzheimer's disease
EP3600328A4 (en) 2017-03-24 2021-01-06 3100 Central Expressway LLC MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CN114306370A (zh) * 2021-12-31 2022-04-12 北京悦康科创医药科技股份有限公司 反义寡核苷酸在制备治疗肾癌药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0728218B1 (en) 1993-11-12 2008-01-02 PHRI Properties, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
WO2005076843A2 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
JP2008512490A (ja) 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
TW200630363A (en) 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
TW200720256A (en) 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
CA2630271C (en) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Fused bicyclic mtor inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP1981890A2 (en) 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
ES2780193T3 (es) 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5258331B2 (ja) 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP3338770B1 (en) 2010-03-08 2023-06-07 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
JP5783499B2 (ja) * 2010-03-29 2015-09-24 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
US8709419B2 (en) * 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
GEP201606545B (en) 2010-11-19 2016-09-26 Ecole Polytech 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
HK1214128A1 (zh) 2012-10-05 2016-07-22 Bluelink Pharmaceuticals, Inc. 癌症的治療
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
AU2015209133B2 (en) 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
CN107249638B (zh) 2014-11-07 2021-05-14 人工智能治疗公司 阿匹莫德用于治疗肾癌
ES2734081T3 (es) 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
KR101761573B1 (ko) 2014-12-29 2017-07-26 주식회사 인트론바이오테크놀로지 신규한 장출혈성 대장균 박테리오파지 Ｅｓｃ-ＣＨＰ-1 및 이의 장출혈성 대장균 증식 억제 용도
WO2016126707A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
AU2019299234A1 (en) 2018-07-05 2021-01-14 Mayo Foundation For Medical Education And Research PIKfyve inhibitors
US20210077500A1 (en) 2019-09-12 2021-03-18 Al Therapeutics, Inc. Pikfyve inhibitors for cancer therapy

Also Published As

Publication number Publication date
CN107249638A (zh) 2017-10-13
PL3215158T3 (pl) 2019-11-29
RU2017119065A3 (enExample) 2019-06-05
CA2966359A1 (en) 2016-05-12
EP3215158A1 (en) 2017-09-13
EP3581184A1 (en) 2019-12-18
HUE044557T2 (hu) 2019-11-28
MX2017006015A (es) 2017-11-17
US11166944B2 (en) 2021-11-09
EP3581184B1 (en) 2021-02-24
KR20170098812A (ko) 2017-08-30
ES2741399T3 (es) 2020-02-10
IL251905A0 (en) 2017-06-29
US20190201385A1 (en) 2019-07-04
PT3215158T (pt) 2019-08-23
EP3215158B1 (en) 2019-05-08
RU2017119065A (ru) 2018-12-07
JP2017535601A (ja) 2017-11-30
US20200297706A1 (en) 2020-09-24
AU2015342869A1 (en) 2017-06-15
WO2016073877A1 (en) 2016-05-12
US20170333408A1 (en) 2017-11-23
JP6705828B2 (ja) 2020-06-03
MX377593B (es) 2025-03-10
US10206910B2 (en) 2019-02-19
CN107249638B (zh) 2021-05-14
RU2727802C2 (ru) 2020-07-24
IL251905B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
IL261163A (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2018002782A1 (es) Apósito modificado
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
SI3594238T1 (sl) Sestavki protiteles za zdravljenje tumorja
PT3377516T (pt) Composição para o tratamento do cancro
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
HUE054012T2 (hu) Kombinációs terápia rák ellen
SI3134124T1 (sl) Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
IL250507B (en) Anti-ck8 antibodies for use in the treatment of cancers
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
IL255560B (en) Macropinocytosis in cancer
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX372759B (es) Composiciones para usarse en mejorar la función renal.
PH12016501838A1 (en) Compounds and their methods of use
PL3317300T3 (pl) Dwuswoiste przeciwciała do zastosowania do immunoterapii nowotworu
MX2019002566A (es) Inmunoterapia para poliomavirus.
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: AI THERAPEUTICS, INC. (US)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements